Research Article

You have full text access to this OnlineOpen article

An increased transforming growth factor β receptor type I:Type II ratio contributes to elevated collagen protein synthesis that is resistant to inhibition via a kinase-deficient transforming growth factor β receptor type II in scleroderma

  1. Jaspreet Pannu1,‡,
  2. Elizabeth Gore-Hyer1,†,‡,
  3. Masayoshi Yamanaka1,
  4. Edwin A. Smith1,
  5. Semyon Rubinchik1,
  6. Jian-Yun Dong1,
  7. Stefania Jablonska2,
  8. Maria Blaszczyk2,
  9. Maria Trojanowska1,*

Article first published online: 6 MAY 2004

DOI: 10.1002/art.20225

Issue

Arthritis & Rheumatism

Arthritis & Rheumatism

Volume 50, Issue 5, pages 1566–1577, May 2004

Additional Information

How to Cite

Pannu, J., Gore-Hyer, E., Yamanaka, M., Smith, E. A., Rubinchik, S., Dong, J.-Y., Jablonska, S., Blaszczyk, M. and Trojanowska, M. (2004), An increased transforming growth factor β receptor type I:Type II ratio contributes to elevated collagen protein synthesis that is resistant to inhibition via a kinase-deficient transforming growth factor β receptor type II in scleroderma. Arthritis & Rheumatism, 50: 1566–1577. doi: 10.1002/art.20225

Author Information

  1. 1

    Medical University of South Carolina, Charleston

  2. 2

    Warsaw Medical Academy, Warsaw, Poland

  1. †

    The Burnham Institute, La Jolla, California

  1. ‡

    Drs. Pannu and Gore-Hyer contributed equally to this work.

*Division of Rheumatology and Immunology, Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 912, PO Box 250637, Charleston, SC 29425

Publication History

  1. Issue published online: 6 MAY 2004
  2. Article first published online: 6 MAY 2004
  3. Manuscript Accepted: 30 JAN 2004
  4. Manuscript Received: 11 AUG 2003

Funded by

  • NIH. Grant Numbers: AR-44883, AR-42334
  • Scleroderma Foundation

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (545K)

REFERENCES

  • 1
    LeRoy EC. A brief overview of the pathogenesis of scleroderma (systemic sclerosis). Ann Rheum Dis 1992; 51: 286–8.
  • 2
    Massague J. How cells read TGF-β signals. Nat Rev Mol Cell Biol 2000; 1: 169–78.
  • 3
    Kawakami T, Ihn H, Xu W, Smith E, LeRoy C, Trojanowska M. Increased expression of TGF-β receptors by scleroderma fibroblasts: evidence for contribution of autocrine TGF-β signaling to scleroderma phenotype. J Invest Dermatol 1998; 110: 47–51.
  • 4
    Yamane K, Ihn H, Tamaki K. Epidermal growth factor up-regulates expression of transforming growth factor β receptor type II in human dermal fibroblasts by phosphoinositide 3-kinase/Akt signaling pathway: resistance to epidermal growth factor stimulation in scleroderma fibroblasts. Arthritis Rheum 2003; 48: 1652–66.
    Direct Link:
  • 5
    Ihn H, Yamane K, Kubo M, Tamaki K. Blockade of endogenous transforming growth factor β signaling prevents up-regulated collagen synthesis in scleroderma fibroblasts: association with increased expression of transforming growth factor β receptors. Arthritis Rheum 2001; 44: 474–80.
    Direct Link:
  • 6
    Kubo M, Ihn H, Yamane K, Tamaki K. Up-regulated expression of transforming growth factor β receptors in dermal fibroblasts in skin sections from patients with localized scleroderma. Arthritis Rheum 2001; 44: 731–4.
    Direct Link:
  • 7
    Kubo M, Ihn H, Yamane K, Tamaki K. Upregulated expression of transforming growth factor-β receptors in dermal fibroblasts of skin sections from patients with systemic sclerosis. J Rheumatol 2002; 29: 2558–64.
  • 8
    Denton CP, Zheng B, Evans LA, Shi-wen X, Ong VH, Fisher I, et al. Fibroblast-specific expression of a kinase-deficient type II transforming growth factor β (TGFβ) receptor leads to paradoxical activation of TGFβ signaling pathways with fibrosis in transgenic mice. J Biol Chem 2003; 278: 25109–19.
  • 9
    Mori Y, Chen SJ, Varga J. Expression and regulation of intracellular SMAD signaling in scleroderma skin fibroblasts. Arthritis Rheum 2003; 48: 1964–78.
    Direct Link:
  • 10
    Dong C, Zhu S, Wang T, Yoon W, Li Z, Alvarez RJ, et al. Deficient Smad7 expression: a putative molecular defect in scleroderma. Proc Natl Acad Sci U S A 2002; 99: 3908–13.
  • 11
    Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581–90.
    Direct Link:
  • 12
    Gore-Hyer E, Pannu J, Smith EA, Grotendorst G, Trojanowska M. Selective stimulation of collagen synthesis in the presence of costimulatory insulin signaling by connective tissue growth factor in scleroderma fibroblasts. Arthritis Rheum 2003; 48: 798–806.
    Direct Link:
  • 13
    Rubinchik S, Ding R, Qiu AJ, Zhang F, Dong J. Adenoviral vector which delivers FasL-GFP fusion protein regulated by the tet-inducible expression system. Gene Ther 2000; 7: 875–85.
  • 14
    He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A 1998; 95: 2509–14.
  • 15
    Czuwara-Ladykowska J, Gore EA, Shegogue DA, Smith EA, Trojanowska M. Differential regulation of transforming growth factor-β receptors type I and II by platelet-derived growth factor in human dermal fibroblasts. Br J Dermatol 2001; 145: 569–75.
    Direct Link:
  • 16
    McCaffrey TA, Du B, Fu C, Bray PJ, Sanborn TA, Deutsch E, et al. The expression of TGF-β receptors in human atherosclerosis: evidence for acquired resistance to apoptosis due to receptor imbalance. J Mol Cell Cardiol 1999; 31: 1627–42.
  • 17
    Trojanowska M. Molecular aspects of scleroderma. Front Biosci 2002; 7: d608–18.
  • 18
    McCaffrey TA, Consigli S, Du B, Falcone DJ, Sanborn TA, Spokojny AM, et al. Decreased type II/type I TGF-β receptor ratio in cells derived from human atherosclerotic lesions: conversion from an antiproliferative to profibrotic response to TGF-β1. J Clin Invest 1995; 96: 2667–75.
  • 19
    Roulot D, Sevcsik AM, Coste T, Strosberg AD, Marullo S. Role of transforming growth factor β type II receptor in hepatic fibrosis: studies of human chronic hepatitis C and experimental fibrosis in rats. Hepatology 1999; 29: 1730–8.
    Direct Link:
  • 20
    Bobik A, Agrotis A, Kanellakis P, Dilley R, Krushinsky A, Smirnov V, et al. Distinct patterns of transforming growth factor-β isoform and receptor expression in human atherosclerotic lesions: colocalization implicates TGF-β in fibrofatty lesion development. Circulation 1999; 99: 2883–91.
  • 21
    Frank S, Madlener M, Werner S. Transforming growth factors β1, β2, and β3 and their receptors are differentially regulated during normal and impaired wound healing. J Biol Chem 1996; 271: 10188–93.
  • 22
    Mogford JE, Tawil N, Chen A, Gies D, Xia Y, Mustoe TA. Effect of age and hypoxia on TGFβ1 receptor expression and signal transduction in human dermal fibroblasts: impact on cell migration. J Cell Physiol 2002; 190: 259–65.
    Direct Link:
  • 23
    Silverstein JL, Steen VD, Medsger TA Jr, Falanga V. Cutaneous hypoxia in patients with systemic sclerosis (scleroderma). Arch Dermatol 1988; 124: 1379–82.
  • 24
    Brand T, MacLellan WR, Schneider MD. A dominant-negative receptor for type β transforming growth factors created by deletion of the kinase domain. J Biol Chem 1993; 268: 11500–3.
  • 25
    Inman GJ, Nicolas FJ, Hill CS. Nucleocytoplasmic shuttling of Smads 2, 3, and 4 permits sensing of TGF-β receptor activity. Mol Cell 2002; 10: 283–94.
  • 26
    Nicolas FJ, Hill CS. Attenuation of the TGF-β-Smad signaling pathway in pancreatic tumor cells confers resistance to TGF-β-induced growth arrest. Oncogene 2003; 22: 3698–711.
  • 27
    Zuscik MJ, Rosier RN, Schwarz EM. Altered negative regulation of transforming growth factor β signaling in scleroderma: potential involvement of SMURF2 in disease. Arthritis Rheum 2003; 48: 1779–80.
    Direct Link:
View Full Article (HTML) Get PDF (545K)